Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PT-2385 is a selective HIF-2α inhibitor (Kd<50 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 61.00 | |
2 mg | In stock | $ 89.00 | |
5 mg | In stock | $ 155.00 | |
10 mg | In stock | $ 271.00 | |
25 mg | In stock | $ 433.00 | |
50 mg | In stock | $ 642.00 | |
100 mg | In stock | $ 913.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 128.00 |
Description | PT-2385 is a selective HIF-2α inhibitor (Kd<50 nM). |
Targets&IC50 | HIF2α:<50 nM (Kd) |
In vitro | PT-2385 is a selective antagonist of HIF-2 and inactive for HIF-1α [1]. |
In vivo | PT-2385 inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31) [1]. PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression [2]. |
Animal Research | Animal Model: SCID/beige mice with the 786-O and A498 RCC cell lines. Dosage: 30 or 100 mg/kg. Administration: Oral gavage; twice daily [2] |
Molecular Weight | 383.34 |
Formula | C17H12F3NO4S |
CAS No. | 1672665-49-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (130.43 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PT-2385 1672665-49-4 Angiogenesis Chromatin/Epigenetic Metabolism HIF/HIF Prolyl-Hydroxylase HIF Inhibitor PT2385 inhibit Hypoxia-inducible factors PT 2385 HIF-PH HIFs inhibitor